<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90628">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01785953</url>
  </required_header>
  <id_info>
    <org_study_id>AML-TO-2012</org_study_id>
    <nct_id>NCT01785953</nct_id>
  </id_info>
  <brief_title>Conventional and Experimental Chemotherapy With Allogeneic Transplant in Young Patients With Acute Myeloid Leukaemia</brief_title>
  <acronym>AML</acronym>
  <official_title>CONVENTIONAL AND EXPERIMENTAL CHEMOTHERAPY WITH ALLOGENEIC TRANSPLANT IN YOUNG PATIENTS WITH ACUTE MYELOID LEUKAEMIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera San Giovanni Battista</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera San Giovanni Battista</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluate patients with acute myeloid leukemia (&lt;=66 years),
      treated with conventional and experimental chemotherapy following allogeneic
      transplantation. THis patients have been enrolled from 2000 to 2011 at the Division of
      Hematology, Molinette University Hospital. The purpose of data collection is to assess, with
      retrospective analysis, the clinical outcome divided by risk class and evaluated in patients
      who achieve complete remission after induction therapy and consolidation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Acute myeloid leukemia patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients with acute myeloid leukemia (&lt;=66 years), treated with conventional and
        experimental chemotherapy following allogeneic transplantation. THis patients have been
        enrolled from 2000 to 2011 at the Division of Hematology, Molinette University Hospital.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedetto Bruno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Divisione di Ematologia-Città della Salute e della Scienza di Torino</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benedetto Bruno, MD</last_name>
    <phone>+390116336728</phone>
    <email>benedetto.bruno@unito.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benedetto Bruno, MD</last_name>
    <phone>+390116336728</phone>
    <email>gismm2001@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedetto Bruno, MD</last_name>
      <phone>+390116336728</phone>
      <email>benedetto.bruno@unito.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 6, 2013</lastchanged_date>
  <firstreceived_date>February 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera San Giovanni Battista</investigator_affiliation>
    <investigator_full_name>Benedetto Bruno</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
